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Background: The objective of this study was to determine the upper normal limit of serum 
alanine aminotransferase level in a population-based study in Golestan Province, northeast Iran.  
Methods: From the randomly invited individuals (2,292), 698 out of the 916 males and 1,351 out 
of the 1,376 females participated in the study (participation rate: 76.2% and 98.1%, respectively). 
One hundred and twenty-one participants were excluded due to positive hepatitis B surface 
antigen or hepatitis C virus antibody and/or drinking more than 20 grams of alcohol per day. A total 
of 1,928 participants (1300 females) were included. The upper normal limit of serum alanine 
aminotransferase level was defined as the 95th percentile. 
Results: The upper normal limit of serum alanine aminotransferase level in normal weight and 
nondiabetics was significantly lower than the total study group (36 versus 45 U/L). Serum alanine 
aminotransferase level was independently associated with male gender, body mass index, and 
diabetes mellitus (OR=2.05; 95%CI: 1.44 – 2.94, OR=2.76; 95%CI: 1.84 – 4.13, and OR=2.96; 95%CI: 
1.56 – 5.61, respectively). 
Conclusion: Considering the lower calculated upper normal limit in normal weight nondiabetic 
participants in this study, we recommend setting new upper normal limit for serum alanine 
aminotransferase level. It seems reasonable to set upper normal limit for serum alanine 
aminotransferase level in males and females separately.   
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Introduction 
 
erum alanine aminotransferase (ALT) 
concentration is the most commonly-used 
variable for assessment of the risk of 
mort
S
ality in liver disease.1,2 The current mean 
upper normal limit (UNL) for ALT was 40 (range: 
30 – 50) U/L in previous studies.1,3–8 Such 
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thresholds were introduced when ALT testing was  
a surrogate marker for the screening of non-A 
non-B hepatitis among blood donors and before 
antihepatitis C virus (HCV) testing, and restrictive 
behavioral criteria for donor selection were
implemented.  
The so-called “reference” population was likely 
to include many persons with nonalcoholic fatty-
liver disease (NAFLD), now recognized as the 
most prevalent cause of chronic liver disease in 
developed countries.9–11 The current reference 
ranges for ALT levels probably underestimate the 
frequency of chronic liver disease. 
The UNL varies in different laboratories 
according to the commercial kit used and the 
reference population chosen by each manufacturer
to establish the normal range. In Iran, no UNL has 
yet been established in a large-scale population­
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based study, despite its importance as an aid to the
classification and management of patients with
liver diseases.
Recent studies have shown that serum ALT
levels can be modulated by a number of factors, 
including gender, body mass index (BMI), fasting 
blood glucose, and serum triglyceride levels.12–14 
These factors are usually not taken into account 
when the normal ALT range is determined.
Considering the fact that serum ALT level varies in
different populations, this study was undertaken in 
an Iranian general population for the first time. 
Materials and Methods 
Golestan Province is located in northeast Iran
with 1,700,000 populations. Gonbad and Kalaleh 
are located in Golestan Province. Gonbad has a 
population of 437,960 and the population of
Kalaleh is 154,349.
In autumn 2006, a total of 2,292 (1,376
females, aged 18 – 75 years) inhabitants of villages 
and cities of Gonbad and Kalaleh were randomly
selected by systematic clustering, according to the
house hold number in the health houses, and were 
invited to take part in this study. The protocol used 
in the present study was approved by the Ethical 
Committee of the Digestive Disease Research
Center at Tehran University of Medical Sciences
based on the Declaration of Helsinki.  
The participants were informed about the
objectives of the study. A written informed consent
was obtained and a comprehensive questionnaire 
including history of known hepatic disease, 
medications used currently or during the last six 
months, hypertension, and diabetes mellitus, was 
completed by a trained physician interviewer.
Morning blood samples of each participant were
collected and transferred to Iranian Blood 
Transfusion Organization Research Center under 
appropriate condition. Separation of serum was 
done under aseptic conditions. The sera were
checked for ALT, hepatitis B surface antigen (HBs 
Ag), and hepatitis C virus antibody (HCV Ab). The 
sera were tested for ALT level using Hitachi 
autoanalyzer 704 (Roche, Switzerland) with Pars 
Azmoon reagents kit (Tehran, Iran). HBs Ag was 
measured by Enzygnost HBs Ag 5.0 kit (Dade 
Behring, Germany). HCV Ab was detected by 
enzyme-linked immunosorbent assay (ELISA)
method using Anti-HCV-EIA-Avicenna kit 
(Moscow, Russia). HCV recombinant immunoblot
assay III using INNOLIATM HCV-Score kit 
(Innogenetics, Gent, Belgium) was carried out on
the positive samples of HCV by ELISA method. 
Those who had positive HCV recombinant 
immunoblot assay III test were considered as 
exposed to HCV. BMI was calculated by dividing 
weight in kilogram to the squared height in meter. 
We considered a BMI≥25 kg/m2 as overweight.15 
Diabetes mellitus and hypertension were defined if 
the participant was a known case of those diseases 
(diagnosed by a physician, received medications,
or had nutritional restrictions). UNL introduced by
the manufacturer for ALT kit was 40 U/L. UNL of 
serum ALT was considered as 95th percentile for 
the serum ALT level, and was measured separately 
considering gender, BMI, and diabetes mellitus 
status. All data were analyzed by SPSS software,
version 13 (Chicago, IL, USA). Proportions were 
compared by Chi-square test. Multivariate analysis 
was performed to identify factors independently 
associated with serum ALT>40 U/L. P values 
<0.05 were considered statistically significant. 
Results
Of the invited individuals (2,292), 698 out of
the 916 males and 1,351 out of the 1,376 females 
participated in the study (participation rate: 76.2% 
and 98.1%, respectively). One hundred and 
twenty-one participants were excluded due to
positive HBs Ag, positive HCV Ab, and/or
drinking more than 20 grams of alcohol per day.
A total of 1,928 participants (1300 females) 
were included. The mean age of the participants 
was 40.7±14.7 (range: 18 – 75) years. The mean
serum ALT level was 20.48±13.1 U/L and the 
mean BMI was 26.12±5.09 kg/m2. 
The mean serum ALT level was significantly 
higher in males (23.03±13.93 U/L) than females 
(19.24±12.5 U/L) (P<0.001); in subjects with 
BMI≥25 (22.94±14.27 U/L) than those with BMI< 
25 (17.51±10.82 U/L) (P<0.001); and also in 
diabetics (28.70±19.93 U/L) than nondiabetics
(20.12±12.62 U/L) (P<0.001). Table 1 indicates 
UNL for serum ALT level considering BMI and
diabetes mellitus in total study sample and also
separately according to gender. 
Figure 1 shows the correlation between serum
ALT level and BMI in men and women.
Logistic regression analysis showed that male
gender (OR=2.05; 95%CI: 1.44 – 2.94), BMI≥25 
(OR=2.76; 95%CI: 1.84 – 4.13),  and  diabetes 
mellitus (OR=2.96; 95%CI: 1.56 – 5.61) were 
independent risk factors for serum ALT level>40 
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Table 1. The upper normal limit for serum alanine aminotransferase levels considering body mass index and diabetes 
mellitus status. 
 UNL for serum ALT levels 
Status (U/L) 
Male Female Total
BMI<25 kg/m2 and nondiabetics (n=859)   37.5 36  36.1 
 
BMI<25 kg/m2 (n=875)    37.85 36 36.2 
BMI ≥ 25 kg/m2 (n=1053) 59 5145.25 
Diabetics (n=79)  51 80.5 77 
Diabetics  and BMI ≥25 kg/m2 (n=63)      60 85 79.4 
Nondiabetics (n=1849) 48.5 4539.85 
Total (n=1928) 50.55 4541.95 
UNL=upper normal limit; ALT=alanine aminotransferase; U/L=unit per liter; BMI=body mass index; kg/m2=kilogram per square meter. 
U/L.  Hypertension  did not  have  any correlation established values for normal ALT range are still 
with serum ALT level. accurate. They have suggested that the upper limit 
 of normal range should be revised.12–14 To the best 
Discussion  of our knowledge, this is the first population- 
 based study conducted in Iran that determined the 
Serum ALT level, a sensitive indicator of liver UNL for serum ALT level. A previous study 
cell injury, has been used to identify patients with conducted in Iran on 1939 blood donors showed 
liver disease for almost 50 years.3 It has been that UNL in Iranian blood donors was 40 U/L in 
recently suggested as a predictor of overall men and 34 U/L in women.12 However, the sample 
mortality and medical costs.16 Several studies have studied was not representative of the general 
recently questioned whether the previously- population. Blood donors in Iran are volunteers 
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Figure 1. Association between serum alanine aminotransferase levels and body mass index in males and females. 
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with healthy behaviors and usually do not include 
obese or underweight subjects, alcohol or 
medication users, or those with severe chronic 
diseases.   
A large-scale population-based study by Kariv 
et al. showed that the UNL of serum ALT level in 
a subgroup of the study sample who had normal 
triglyceride, cholesterol, glucose, negative viral 
and autoimmune markers, normal BMI, and those
who used no hepatotoxic drugs or alcohol (37.5
U/L) was lower than the UNL calculated in total 
study sample which was selected at random from 
the general population (50.1 U/L).13 
Prati et al. calculated the “healthy” range for 
serum ALT level in blood donors who had a 
normal BMI and normal serum cholesterol, 
triglyceride, and glucose levels and were not taking
medications. The calculated UNL for ALT level
decreased from 40 U/L to 30 U/L in men and from
30 U/L to 19 U/L in women.14 In this study, after 
excluding the subjects with overweight or diabetes, 
the UNL of serum ALT level was significantly
lower than the total study group (36 versus 45 
U/L). This finding is comparable to the previous 
studies.13,14  
Considering the high prevalence of over-
weights (54.6%) in our study, which is comparable 
to the previous studies conducted in this area,17,18
the calculated UNL for the whole study sample (45 
U/L) cannot be used as the UNL for healthy
individuals. The UNL calculated for the subgroup 
of the study sample with BMI<25 kg/m2 (36.2
U/L) was lower than that for the total study sample 
and even the current upper thresholds (40 U/L) 
proposed by the ALT kit manufacturer.  
The UNL in those with normal weight and non-
diabetic individuals (men: 37.5 U/L; women: 36
U/L) was near to the previously reported UNL for 
Iranian blood donors (men: 40 U/L; women: 34
U/L).12 The results also showed that UNL in non-
diabetics (45 U/L) was lower than diabetics (77 
U/L). This most probably reflects the effect of
diabetes mellitus as a component of metabolic 
syndrome by inducing NAFLD on serum ALT 
level. There is evidence showing that abnormal 
carbohydrate metabolism results in elevation of
serum ALT level.14,19–20 
In this study, the UNL for serum ALT level was 
significantly higher in overweight males than 
females (59 versus 45.25 U/L). This is comparable 
with the previous study showing the more strong 
effect of overweight in males in increasing the 
serum ALT level than in females.21 The previous 
study for determining UNL in Iranian blood donors 
also clarified that serum ALT level was 
independently associated with BMI and male
gender. And association of ALT with BMI was
more prominent in males than in females.12 
Our study also determined the correlation 
between serum ALT levels and male gender, 
BMI≥25 kg/m2, and diabetes mellitus. It showed
new thresholds for the UNL of serum ALT level 
according to gender, BMI, and the presence of 
diabetes mellitus. This study further emphasized 
the findings of the previous studies regarding the
strong association of serum ALT level with male
gender and BMI.12,14,22–25 
Diabetes mellitus and overweight are both 
components of metabolic syndrome. NAFLD is the 
hepatic manifestation of metabolic syndrome and 
the commonest etiology of elevated serum ALT
level in Iran.26,27 This explains the observed
elevation of serum ALT level in overweights and 
diabetics in this study. The study of Iacobellis et 
al.19 showed that elevated serum ALT level was 
associated with increased fasting insulin and not 
with obesity per se. They suggested that the 
presence of insulin resistance, rather than BMI 
alone, plays a role in mediating the increased
aminotransferase levels.19,20 
We should emphasize that UNL calculated in 
this study is the 95th percentile for serum ALT 
level in the studied population and does not 
appropriately set the healthy serum ALT level
which may predict the over all mortality. Lack of 
measurement of serum triglyceride, cholesterol,
and fasting glucose, which influence on serum
ALT level is the limitation of this study. 
The previous studies in Iran, Korea, and Jordan 
have shown that the prevalence of diagnosed
diabetes mellitus in adult population was about 4% 
and if screening with fasting plasma glucose was
used, the prevalence would be increased to 7%.28–30 
Although screening with fasting plasma glucose 
was not performed in our study, the prevalence of 
diagnosed diabetes mellitus was 4%, which is
comparable with the previous studies mentioned 
above. 
In conclusion, considering the lower calculated 
UNL in normal-weight, nondiabetic participants in
this study, we recommend setting new UNL for
serum ALT level. The new threshold for serum
ALT level increases the sensitivity of the test for 
early diagnosis and follow-up of patients with liver 
diseases. It seems reasonable to set UNL for serum
ALT level in males and females separately.
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The UNL of ALT in Golestan Province 
However, considering the BMI for redefinition of
the UNL is not recommended because elevated
levels in overweights may be a clue to the 
diagnosis of NAFLD. Therefore, adjusting the 
UNL for overweights will result in underdiagnosis 
of some patients with NAFLD. 
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